Dendreon seeks Chapter 11 bankruptcy as $620m debt looms
This article was originally published in Scrip
Dendreon said late on 9 November that it has reached an agreement with certain holders of its convertible senior notes due in 2016 to seek Chapter 11 bankruptcy so that it can reorganize, sell the company or dispose of its assets to manage $620m in debt that must be repaid in 14 months.
You may also be interested in...
Brainstorm’s president and CEO Chaim Lebovits talks to Scrip about the company’s progress with personalized stem cell therapy NurOwn in ALS and what the future holds for cell therapy options in neurology.
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?